Drug data last refreshed 43m ago · AI intelligence enriched 2w ago
CHOLOGRAFIN SODIUM is a legacy injectable diagnostic agent approved in 1954 by Bracco, used as a contrast medium for radiographic imaging procedures. The drug facilitates visualization of the biliary system and related anatomical structures during medical imaging. It represents an older class of iodinated contrast agents with established clinical utility in hepatobiliary imaging.
Product is in late lifecycle with moderate competitive pressure (30), indicating potential team consolidation and focus on retention over growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Careers linked to CHOLOGRAFIN SODIUM reflect a maintenance-mode portfolio asset with zero active job postings, indicating limited hiring and team expansion. Roles available are typically operational, regulatory, or sales-focused rather than innovative or strategic development positions.
Worked on CHOLOGRAFIN SODIUM at Bracco? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.